US Patents for Sale
Accelerated Therapeutics is a term we have long used to describe a known safe drug that can be repurposed to treat a new indication, and can be expected to provide a superior therapeutic benefit, based on known biochemical pathways and mechanisms of action. We already have US patents for 2 such opportunities.
The value proposition to patients is a superior treatment option, without horrific side effects, and at a fraction of the cost of expensive proprietary drug regimens.
The value proposition to an investor is a low cost, low risk, short time to market opportunity.
Two Already Patented Opportunities:
1) HER1 (EGFR) Receptor Modulated Cancer Protocols (U.S.: $ 5 Billion Available Market)
Cancer Opportunity - Science and Market Information (PDF)
2) Calcium Ion (Ca++) Homeostasis for Epilepsy/ Seizures (U.S.: $ 3 Billion Available Market)
Neurology Opportunity - Science and Market Information (PDF)
Clinical Development Advantage:
Repurposing can typically be started in a Phase II human proof of efficacy setting, as the drugs have not only passed Phase I human safety trials, but also have established safety from Phase II trials, Phase III trials, and extended human use in other indications. This allows for a short time to market, at low risk and low cost, in stark contrast to the very expensive, high risk, and extremely long time to market required for new drug development.
Step 1: Our process starts with a Mechanism of Action (MOA) intensive approach of mapping out the molecular pathways underlying the etiology and pathology (pathogenesis) of a disease condition. Repurposing candidates are then identified on mechanistic ability to inhibit either the earliest pathways of the etiology or to inhibit the largest number of pathways in the pathogenesis.
Step 2: Related human clinical data is then reviewed for consistency with the novel pathogenesis and for support for the MOA selected to inhibit the pathogenesis. Academia published studies are avoided when possible because of their high unreliability rate (e.g. Amgen found 47 of the 53 landmark oncology studies published by academia were not reproducible).
Step 3: The final step is evaluating if the proposed treatment can be expected to provide a therapeutically superior treatment option relative to the current best standard of care.
Contact Info: If you have interest in any of the above therapeutic areas, please contact Mark Zamoyski, email@example.com
© 2018 Mark J. Zamoyski